South Korean pharmaceutical scientists are developing innovative retinal drug formulations that aim to improve absorption, extend therapeutic duration, and minimize ocular discomfort. Traditional approaches requiring frequent injections pose challenges for both patients and providers, leading researchers to design solutions such as long-acting particles, biodegradable implants, and nano-structured drug carriers. These technologies allow drugs to remain active inside the eye for longer periods, reducing clinical visits and enhancing patient compliance. Korean biotech labs also explore topical and orally delivered retinal drugs, aiming to increase convenience while exploring alternative delivery pathways.

The country’s interest in regenerative medicine further influences retinal drug design. Research into cell-derived exosomes, growth factors, and peptide therapies opens doors for neuroprotective and tissue-restorative treatments. Ophthalmologists increasingly collaborate with biomedical engineers to test new formulations and monitor their impact using advanced ocular imaging. Patients gain access to innovative therapies that help stabilize or improve visual function. Through a combination of advanced formulation science and strong clinical collaboration, South Korea continues to push boundaries in retinal drug development.